Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Relapsed/Refractory ALK+ ALCL
NCT03703050Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Jan 2019
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of nivolumab in anaplastic large cell lymphoma (ALCL) (2 cohorts), sponsored by Gustave Roussy. Primary endpoints: Best Objective Response Rate at 24 weeks and Progression-Free Survival at 12 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03703050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703050.